This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08950/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n6http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB08950/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB08950/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://www.drugs.com/international/

Statements

Subject Item
n2:DB08950
rdf:type
n3:Drug
n3:description
Indoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese. It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.
n3:group
withdrawn
owl:sameAs
n6:DB08950
dcterms:title
Indoramin
adms:identifier
n8:Indoramin n9:DB08950 n10:D04531
n3:synonym
Indoramina Indoramine
n3:salt
n3:synthesisReference
U.S. Patent 3,527,761
foaf:page
n13:indoramin.html
n3:IUPAC-Name
n4:271B5F24-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5F2A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5F29-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5F26-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5F27-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5F28-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5F22-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5F20-363D-11E5-9242-09173F13E4C5 n4:271B5F23-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5F21-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5F30-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5F31-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5F2B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5F2C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5F2E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5F2D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5F2F-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
26844-12-2
n3:Bioavailability
n4:271B5F36-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5F38-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5F39-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5F3A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5F35-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5F34-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5F37-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5F25-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5F32-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5F33-363D-11E5-9242-09173F13E4C5